Display options
Cite
Lee VW, Lam YY, Yuen AC, et al. Direct medical cost of newly diagnosed stable coronary artery disease in Hong Kong. Heart Asia. 2013;5(1):1-6doi: 10.1136/heartasia-2012-010168.
Lee, V. W., Lam, Y. Y., Yuen, A. C., Cheung, S. Y., Yu, C. M., & Yan, B. P. (2013). Direct medical cost of newly diagnosed stable coronary artery disease in Hong Kong. Heart Asia, 5(1), 1-6. https://doi.org/10.1136/heartasia-2012-010168
Lee, Vivian W Y, et al. "Direct medical cost of newly diagnosed stable coronary artery disease in Hong Kong." Heart Asia vol. 5,1 (2013): 1-6. doi: https://doi.org/10.1136/heartasia-2012-010168
Lee VW, Lam YY, Yuen AC, Cheung SY, Yu CM, Yan BP. Direct medical cost of newly diagnosed stable coronary artery disease in Hong Kong. Heart Asia. 2013 Jan 02;5(1):1-6. doi: 10.1136/heartasia-2012-010168. eCollection 2013. PMID: 27326062; PMCID: PMC4832635.
Copy Download .nbib Format: NLM
Share it on

Heart Asia. 2013 Jan 02;5(1):1-6. doi: 10.1136/heartasia-2012-010168. eCollection 2013.

Direct medical cost of newly diagnosed stable coronary artery disease in Hong Kong.

Heart Asia

Vivian W Y Lee, Yat Yin Lam, Amy C M Yuen, Shuk Yan Cheung, Cheuk-Man Yu, Bryan P Y Yan

Affiliations

  1. School of Pharmacy, Faculty of Medicine , The Chinese University of Hong Kong , Shatin , Hong Kong.
  2. Department of Medicine and Therapeutics, Faculty of Medicine , The Chinese University of Hong Kong , Shatin , Hong Kong.

PMID: 27326062 PMCID: PMC4832635 DOI: 10.1136/heartasia-2012-010168

Abstract

BACKGROUND: Stable coronary artery disease (CAD) affects approximately 7% of the population of Hong Kong and is associated with substantial healthcare costs.

OBJECTIVE: We aimed to evaluate the first-year direct medical cost for a patient with newly diagnosed stable CAD at a tertiary care public hospital in Hong Kong and to identify CAD-related resource consumption pattern among different patient subgroups.

METHODS: 89 consecutive patients with newly diagnosed stable CAD at our institution from January 2007 to December 2009 were retrospectively analysed. Direct medical costs including hospitalisation, clinic visits, diagnostic tests, laboratory tests, invasive procedures and medications were calculated for 1 year after diagnosis. Mann-Whitney tests were performed to compare median costs in patients with and without hypertension, diabetes mellitus and hyperlipidaemia, and in patients undergoing coronary intervention and those who were not.

RESULTS: The mean first-year total direct medical cost of newly diagnosed stable CAD per patient was US$11 477. Hospitalisation was the dominant cost item accounting for 29.2% of the total cost. The total cost for patients who underwent invasive coronary procedure was higher than those treated medically alone (US$14 787 vs US$6121, p<0.001). Hyperlipidaemia was associated with higher incremental costs than hypertension and diabetes mellitus (p<0.001). (1US$=7.8HK$).

CONCLUSIONS: Huge healthcare expenses are incurred in the first year of stable CAD diagnosis from the perspective of the local public healthcare system. Healthcare costs are highest among patients with hyperlipidaemia and those undergoing invasive coronary procedures (even discounting costs for procedural consumables). Strategies for cost saving and preventive measures should be implemented to lower healthcare expenditure associated with CAD.

References

  1. Nutr Metab Cardiovasc Dis. 2010 Jul;20(6):426-35 - PubMed
  2. Arq Bras Cardiol. 2005 Jul;85(1):3-8 - PubMed
  3. Heart. 2003 Aug;89(8):848-53 - PubMed
  4. Can J Cardiol. 2008 Oct;24(10):759-64 - PubMed
  5. Am J Manag Care. 2004 Oct;10(11 Suppl):S358-69 - PubMed
  6. Eur Heart J. 2006 Jun;27(11):1341-81 - PubMed
  7. Circulation. 2005 Jun 7;111(22):2906-12 - PubMed
  8. Lancet. 2005 Oct 8;366(9493):1267-78 - PubMed

Publication Types